VectorialDATA
Stocks/NVO

NVO — Novo Nordisk A/S

HealthcareEuropeDenmarkBlockchain certified

Price when we picked it (Oct 5, 2026)

$36.94

Target: $46.01 (+24.6%)

P/E Ratio

9.4

P/E Forward

11.1

Dividend

4.8%

Market Cap

$162.9B

EPS

$3.93

Consensus

Hold

What they do

Novo Nordisk A/S (headquartered at Novo Allé 1, Bagsværd, on the outskirts of Copenhagen, Denmark; it has made insulin since 1923, and the current company was born in 1989 from the merger of Nordisk Gentofte and Novo Industri; CEO Maziar Mike Doustdar since August 7, 2025; 68,794 full-time employees as of December 31, 2025) is one of the world leaders in medicines for obesity and diabetes and sells in ~170 countries. Its star is semaglutide, a molecule that mimics a gut hormone (GLP-1): it tells the brain you have already eaten — which is why it curbs hunger — and helps the body control blood sugar. With it the company makes Ozempic (a weekly injection for diabetes: DKK 31,375 million in sales in April–June 2026), Wegovy (the same molecule dosed for weight loss: DKK 19,484 million as an injection and DKK 3,218 million as the new daily pill) and Rybelsus (a diabetes pill, also sold in the US as the Ozempic pill: DKK 5,228 million). Together they make up ~76% of its sales. It also sells insulins (DKK 12,941 million in the quarter) and medicines for rare diseases — haemophilia and growth hormone (DKK 4,907 million). The US is 52% of its sales.

Key detail for investors: what you buy in New York is an ADR (NYSE: NVO), and each ADR equals 1 B share traded in Copenhagen (NOVO B; depositary JPMorgan Chase Bank). On October 2, 2026 the B share closed in Copenhagen at DKK 248.75: at ~6.65 kroner per dollar that is ~$37.40, practically the ADR price. Market value is ~$162.9 billion. Every per-share figure the company publishes — profit, dividend — is in Danish kroner: for the ADR you simply convert it to dollars. The company is controlled by the Novo Nordisk Foundation, which through Novo Holdings held ~77% of the votes with ~28% of the shares (November 2024 data).

Why we like it

Three reasons.

  • THE PILL IS WORKING: the Wegovy pill, launched in the US on January 5, 2026, passed 265,000 prescriptions a week (week ending July 17) and 5 million since launch — according to the company, the highest-volume launch ever for a medicine of this type in the US — at $149 to $299 a month for people paying out of pocket. In April–June it sold DKK 3,218 million, obesity sales grew 16% and sales outside the US rose 10%. That is why on August 4 it improved what it expects for 2026: sales and operating profit of 0% to −6% (in May it expected −4% to −12%).
  • IT PAYS YOU WHILE YOU WAIT: it paid out DKK 11.70 per share for 2025 (+2.6%), ~4.8% a year on $36.94 and ~51% of what it earned; in the first half of 2026 it returned DKK 41.2 billion to its owners (DKK 35.3 billion in dividends and DKK 5.9 billion buying back its own shares), it expects DKK 45 to 55 billion of free cash for the year (what is left after running the business and investing in factories), and on September 21 it promised to 'maintain an attractive dividend per share'.
  • THE PRICE ALREADY BAKES IN A LOT OF FEAR: the stock is worth 75% less than in June 2024 ($148.15), even though in 2025 it earned DKK 102,434 million — the highest profit in its history — and analysts expect its earnings per share to fall only ~1% in 2026 and ~3% in 2027. At $36.94 it costs ~11 times the profit it is expected to make in 2027; Eli Lilly, its big rival (which we already own since pick #134), costs ~24 times. Hold consensus from 12 analysts with an average target of $46.01 (+24.6%).

Key Risk

The #1: it depends on a single molecule, and its patents are running out. Semaglutide (Ozempic, Wegovy and Rybelsus) was ~76% of April–June 2026 sales. In 2026 its patents expired in China, India and Brazil — in India copies came out almost immediately — and in Canada the government approved a Dr. Reddy's copy on April 28, 2026, because Novo let its patent lapse in 2019 by not paying a fee. In the US, 52% of its sales, the patent expires in 2032. 'This is what's on most people's mind, and rightfully so,' its CEO said on September 21. Others:

  • Eli Lilly is gaining ground: in April–June Lilly had ~61% of the obesity medicine market and Novo ~39%; and CagriSema, Novo's next big bet, achieved 23.0% weight loss versus 25.5% for Lilly's medicine in an 84-week head-to-head trial (the stock fell 16% on February 23, 2026);
  • falling prices in the US: under a deal with the government, from January 1, 2027 the list price of Wegovy drops ~50% and Ozempic's ~35% (to $675 a month), and out of every 100 kroner it sells it now keeps 78.2 after manufacturing, versus 82.7 a year earlier;
  • research setbacks: the ZEUS trial of a heart medicine failed (the stock fell 8.8% on July 31, 2026) and in the quarter it wrote off DKK 6.3 billion in projects, including monlunabant (DKK 4.0 billion);
  • a year of falling sales: it expects 2026 sales between 0% and −6%, and its 2030 targets — growing 'in line with peers' — disappointed: the stock fell ~8% that day;
  • taxes and currency: the dividend is declared in Danish kroner, Denmark withholds 27% and getting the difference back down to 15% takes paperwork; on top of that, a late-2025 ruling by Denmark's tax tribunal cast doubt on whether ADR holders are entitled to that refund;
  • control: the Novo Nordisk Foundation holds ~77% of the votes, so minority shareholders have almost no say.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked NVO on Oct 5, 2026 at $36.94.

Full Research

What it does. Novo Nordisk A/S (NYSE: NVO; Copenhagen: NOVO B; headquartered at Novo Allé 1, Bagsværd, Denmark; CEO Maziar Mike Doustdar since August 7, 2025, with the company since 1992; chair of the board Lars Rebien Sørensen since November 14, 2025; 68,794 full-time employees as of December 31, 2025, versus 76,302 a year earlier, after a restructuring in which ~9,000 people left) was born in 1989 from the merger of Nordisk Gentofte — which began producing insulin in 1923, founded by August Krogh, H.C. Hagedorn and A. Kongsted — and Novo Industri (1925). It sells in ~170 countries and reports two segments: Obesity and Diabetes (Wegovy, Ozempic, Rybelsus, insulins) and Rare Disease (haemophilia, growth hormone). In the first half of 2026 it served 41.6 million people with diabetes and 4.9 million with obesity; Wegovy is already sold in ~60 countries. Its core molecule is semaglutide, which mimics the GLP-1 hormone: it reduces hunger and helps control blood sugar. Adjusted sales by brand in April–June 2026 (growth excluding currency effects): Ozempic DKK 31,375 million (+5%), Wegovy injectable DKK 19,484 million (+1%), Wegovy pill DKK 3,218 million, Rybelsus / Ozempic pill DKK 5,228 million (−4%), insulins DKK 12,941 million (+6%) and rare diseases DKK 4,907 million (+6%). Semaglutide added up to DKK 59,305 million, ~76% of the total. In 2025 Wegovy sold DKK 79,106 million (+36%) and Ozempic DKK 127,089 million.

The ADR. Each ADR equals 1 B share (2025 20-F: 'American Depositary Receipts, each representing one B Share'); depositary J.P. Morgan (JPMorgan Chase Bank, N.A.). One ADR carries the same votes as one B share. On October 2, 2026 the B share closed in Copenhagen at DKK 248.75: at ~6.65 kroner per dollar ≈ $37.40, in line with the ADR ($37.32 at that day's close). There are 4,460 million A and B shares and the company held 50.6 million in treasury as of October 2, 2026: ~4,409 million outstanding × $36.94 ≈ $162.9 billion market value. Novo Holdings A/S, owned by the Novo Nordisk Foundation, held 28.05% of the capital and 77.28% of the votes as of November 8, 2024; its A shares cannot be sold as long as the Foundation exists, and the Foundation's chair (Lars Rebien Sørensen) also chairs Novo Nordisk's board.

Results (second quarter of 2026, reported on August 4, 2026). Reported sales of DKK 78,488 million (+2% in kroner, +3% excluding currency effects); adjusted, +6% and +7%, because in the second quarter of 2025 there was a one-off gain of DKK 2.6 billion from releasing a provision for the US 340B program (mandatory discounts to hospitals that serve low-income patients). Obesity DKK 23,152 million (+16%); diabetes DKK 50,429 million (+3%); US DKK 40,869 million (+4% adjusted) and international DKK 37,619 million (+10%). Reported operating profit of DKK 27,061 million (−16%), hit by DKK 6.3 billion of non-cash charges for research projects written off (monlunabant, DKK 4.0 billion); adjusted, DKK 33,389 million (+11%), with a 42.5% margin. Gross margin of 78.2% versus 82.7% a year earlier, due to lower prices, ~DKK 3 billion of one-time costs to resize manufacturing capacity contracts, and currency. Net profit of DKK 20,989 million (−21%); adjusted, DKK 27,421 million (+5%). Diluted earnings per share of DKK 4.75 (−20%); adjusted, DKK 6.18 (+5%). Half year: reported sales of DKK 175,311 million (+18% excluding currency effects, inflated by the release of DKK 26,760 million of the 340B provision in the first quarter, with no cash effect); adjusted, DKK 148,551 million (+2%); net profit of DKK 69,546 million; earnings per share of DKK 15.66; free cash flow of DKK 55.3 billion (+44%). At the half-year average exchange rate (6.40 kroner per dollar), quarterly sales equal ~$12.3 billion and adjusted operating profit ~$5.2 billion. Full year 2025 (reported on February 3, 2026): sales of DKK 309,064 million (+10% excluding currency effects), net profit of DKK 102,434 million (+1%) and earnings per share of DKK 23.03 (+2%).

The Wegovy pill. Launched in the US on January 5, 2026; in the OASIS 4 trial it achieved 16.6% average weight loss. More than 265,000 prescriptions a week in the week ending July 17, ~2.9 million in the quarter and more than 5 million since launch: according to the company, 'the strongest-ever GLP-1 volume launch in the US'. It is sold in more than 70,000 pharmacies and through nine telehealth platforms, at $149–$299 a month for people paying out of pocket. Approved in the European Union in July 2026 and launched in the United Arab Emirates (June) and the United Kingdom (July). Wegovy HD (7.2 mg; up to 20.7% weight loss in the STEP UP trial) launched in the US on April 7, 2026. Measured by new patients, the Wegovy family remains the leading obesity brand in the US; weekly Wegovy prescriptions (injection + pill) reached ~575,000.

What it expects. 2026 (improved on August 4): adjusted sales of 0% to −6% excluding currency effects (before −4% to −12%; the initial target on February 3 was −5% to −13%) and adjusted operating profit of 0% to −6%; free cash flow of DKK 45 to 55 billion; investment in factories of ~DKK 55 billion. It assumes lower prices ('Most Favoured Nation' agreement with the US government, signed in November 2025), tougher competition, less Medicaid coverage and the expiry of semaglutide patents in some countries. From January 1, 2027 it will cut the list price of Wegovy and Ozempic to $675 a month (~50% and ~35% less), with an impact on 2027 cash flow. Capital Markets Day (London, September 21, 2026), 2030 ambitions that are not formal guidance: launch more than 5 multi-billion-dollar medicines; more than DKK 150 billion in sales from its new-medicines pipeline in 2035 (risk-adjusted); serve more than 60 million patients; multiply its oral GLP-1 capacity for obesity by 10; grow revenue from 2026 to 2030 'in line with industry peers' (Eli Lilly, AstraZeneca, J&J, AbbVie, Novartis, Roche, Merck, Pfizer, among others), with a 'broadly stable' operating margin and an 'attractive dividend per share'. The stock fell ~8% that day. On September 23, Doustdar said he is open to considering a direct listing on the New York Stock Exchange instead of the ADR, though he clarified the company is not actively exploring it.

Dividend and capital. It pays twice a year, in kroner per share: a final 2025 dividend of DKK 7.95 (approved at the March 26, 2026 general meeting; ~$1.275 per ADR according to Yahoo) and an interim 2026 dividend of DKK 3.75 (ADR ex-dividend on August 17 and payment on August 25, 2026; ~$0.579 per ADR). Total for 2025: DKK 11.70 (+2.6% versus DKK 11.40 for 2024), ~51% of 2025 earnings per share (DKK 23.03). At ~6.66 kroner per dollar, DKK 11.70 = ~$1.76 per ADR: ~4.8% on $36.94 (with the dollars actually paid, $1.275 + $0.579 = $1.85, ~5.0%). The next dividend for someone buying at $36.94 is the final 2026 dividend: the 2025 one was proposed with the annual results on February 3, 2026 and paid after the March general meeting. Buybacks: a program of up to DKK 15 billion over 12 months starting February 4, 2026; by October 2 it had bought 36.6 million B shares for DKK 10,247 million (average price of DKK 279.95, above that day's close of DKK 248.75). In the first half it returned DKK 41.2 billion (DKK 35.3 billion in dividends and DKK 5.9 billion in buybacks). Credit rating: Aa3 (Moody's) and AA (S&P).

Taxes. Denmark withholds 27% of the dividend for anyone who does not live in Denmark. If your country has a tax treaty with Denmark, the maximum rate falls — 15% for the US, Mexico, Canada, the United Kingdom, Chile and Argentina; 25% for Brazil and India (Clearstream treaty table) — but it is not automatic: 27% is withheld and you then ask the Danish tax authority to refund the difference, with documents (for US ADR holders: the Danish claim form, IRS Form 6166, proof of ADR ownership and of the dividend received), within three years of the payment; the depositary provides the information (JPMorgan Chase Bank, via Globe Tax Services). Note: according to the 2025 20-F, in late 2025 Denmark's National Tax Tribunal (Landsskatteretten) issued a ruling that creates uncertainty over whether ADR holders count as 'shareholders' for Danish tax purposes and, therefore, whether they can claim that refund. Our calculation on $36.94: ~4.8% gross; ~3.5% net with the 27% withholding; ~4.0% net if the difference down to 15% is recovered. What each investor pays in their own country depends on local rules (many countries allow a credit for foreign tax). Denmark does not tax the gain on selling the ADR for people who do not live there.

The stock. $36.94 at the open (October 5, 2026) on the NYSE. ADR 52-week range: $35.12 (March 30, 2026) to $64.16 (January 23, 2026): 42% below the high and 5% above the low; in Copenhagen, DKK 224.25 to DKK 409.95. ADR all-time high: $148.15 (June 25, 2024); the purchase price is 75% below it. Drops in 2026: −14.6% on February 3 (initial target of falling sales), −16.4% on February 23 (CagriSema versus Lilly), −8.8% on July 31 (ZEUS trial failure) and −8% on September 21 (2030 targets). Between March 30 and July 30 it rose from $35.29 to $51.61 (+46%) on the Wegovy pill launch, and it has fallen 28% since then. Diluted earnings per share over the last 12 months: DKK 26.20 (DKK 15.66 from the first half of 2026 + DKK 10.54 from the second half of 2025) ≈ $3.93 per ADR: P/E (price vs. profit) ~9.4x, though it includes the one-off release of DKK 26,760 million of the 340B provision. On what analysts expect (Yahoo, 8 analysts): DKK 22.73 for 2026 (~$3.41; ~10.8x) and DKK 22.10 for 2027 (~$3.32; ~11.1x). Eli Lilly trades at ~24 times its expected profit and ~38 times its last-12-month profit (Yahoo). Consensus of 12 analysts with a target (Yahoo): Hold, average target of $46.01 (range $39.15–$61.95), +24.6% above the purchase price; of 14 recommendations, 3 are buy, 10 hold and 1 sell. Next quarterly report: November 4, 2026.

Competition and patents. Eli Lilly (tirzepatide: Mounjaro and Zepbound; the Foundayo pill, launched in April 2026) had ~61% of the obesity medicine market in the second quarter of 2026, versus ~39% for Novo (Proactive, September 21, 2026). CagriSema (cagrilintide + semaglutide), submitted to the FDA on December 18, 2025, achieved 23.0% weight loss versus 25.5% for tirzepatide in the REDEFINE 4 trial (84 weeks; 20.2% versus 23.6% counting people who stopped treatment) and missed its main goal of showing it is not inferior (announced February 23, 2026). Semaglutide patents: in the US the compound patent expires in 2032 (20-F); in China, India and Brazil they expired in 2026 — in China and India, on March 20 — and in India generic versions from Torrent, Alkem and others came out almost immediately; in Canada, Health Canada approved Dr. Reddy's generic version on April 28, 2026, because Novo let its patent lapse in 2019 by not paying the maintenance fees. In Europe, Sandoz asked the Unified Patent Court on June 30, 2026 to revoke the patent on the 1 mg diabetes dose in 18 countries; in the US, Cipla sought approval for a generic Ozempic and Novo sued it. Novo, in turn, sued Lilly on July 21, 2026 for false advertising about the comparative efficacy of their medicines. Doustdar, on September 21: 'This loss of exclusivity is what's on most people's mind, and rightfully so.'

Risks. (1) Concentration and patents: semaglutide is ~76% of sales; patents expired in China, India and Brazil, a copy approved in Canada and expiry in the US (52% of sales) in 2032. (2) Competition: Lilly ~61% of the obesity market versus ~39%; CagriSema lost the head-to-head comparison. (3) US prices: deal with the government, list price at $675 from January 1, 2027 (Wegovy −~50%, Ozempic −~35%) and gross margin of 78.2% versus 82.7%. (4) Research: ZEUS (ziltivekimab) failure and DKK 6.3 billion of project charges in the second quarter. (5) 2026 sales expected between 0% and −6% and 2030 targets that disappointed. (6) Taxes and currency: dividend in kroner, 27% Danish withholding and uncertainty about refunds for ADR holders. (7) Control by the Novo Nordisk Foundation (~77% of the votes). (8) Lawsuits: class actions in the US over an IT security incident (announcement of June 11, 2026).

In the portfolio. It complements Eli Lilly (pick #134, July 23, 2026, at $1,146.62): with both, the portfolio owns the two giants of obesity — the one winning the market (Lilly, ~24 times its expected profit) and the beaten-down one (Novo, ~11 times and a ~4.8% dividend). The thesis is not that Novo beats Lilly: it is that at $36.94 the price already reflects the patents and the competition, while the company keeps generating billions of kroner in cash and paying them out.

More picks in Healthcare

See all Healthcare picks →

More picks from Denmark

See all picks from Denmark →
Researched: Oct 5, 2026Updated: Oct 5, 2026Next review: Apr 5, 2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.